The American Journal of Managed Care

Prospective Study in High-Risk Individuals Supports Primary Prevention Trials in MS

A prospective study of first-degree relatives of patients with MS found that this high-risk population faces significantly ...
The New England Journal of Medicine

Inhibition of CD40L with Frexalimab in Multiple Sclerosis

The CD40–CD40L costimulatory pathway regulates adaptive and innate immune responses and has been implicated in the pathogenesis of multiple sclerosis. Frexalimab is a second-generation anti-CD40L ...
Business Wire

Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms ...

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life ...
Science Daily

Multiple myeloma: Cilta-cel found highly effective in real-world study

A new study shows strong alignment between real-world outcomes and those seen in clinical trials among a broad population of patients with relapsed or refractory multiple myeloma. In the first study ...